Cerity Partners LLC Acquires 7,545 Shares of Edwards Lifesciences Corporation $EW

Cerity Partners LLC grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 212,705 shares of the medical research company’s stock after acquiring an additional 7,545 shares during the period. Cerity Partners LLC’s holdings in Edwards Lifesciences were worth $16,542,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Edwards Lifesciences by 1.2% in the second quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after acquiring an additional 798,801 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after purchasing an additional 45,555 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after purchasing an additional 1,584,958 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. Finally, Ninety One UK Ltd raised its holdings in Edwards Lifesciences by 14.0% during the 3rd quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after buying an additional 969,030 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.7%

EW opened at $85.14 on Friday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average is $85.06 and its two-hundred day moving average is $80.32. The company has a market capitalization of $49.41 billion, a P/E ratio of 36.70, a PEG ratio of 3.44 and a beta of 0.95. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 31st. Evercore ISI reissued an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday. Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Finally, TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $90.00 to $97.00 in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 57,824 shares of company stock valued at $4,863,323. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.